Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

41. Notice to SGO Members: Emerging data on the surgical approach for radical hysterectomy in the treatment of women with cervical cancer

Notice to SGO Members: Emerging data on the surgical approach for radical hysterectomy in the treatment of women with cervical cancer

Society of Gynecologic Oncology2018

42. Committee Opinion: Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer

Committee Opinion: Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer VOL. 131, NO. 1, JANUARY 2018 OBSTETRICS & GYNECOLOGY e31 Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer ABSTRACT: “Cascade testing” refers to the performance of genetic counseling and testing in blood relatives of individuals who have been identified with specific genetic mutations. Testing protocols and other interventions may save lives (...) identification of women with hereditary cancer syndromes. Recommendations and Conclusions The American College of Obstetricians and Gynecologists makes the following recommendations and conclusions regarding genetic cascade testing for hereditary gyneco- logic cancer: • Cascade testing refers to the performance of genetic counseling and testing in blood relatives of individu- als who have been identified with specific genetic mutations. Testing protocols and interventions may save lives and improve health

Society of Gynecologic Oncology2018

43. Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer

Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer 30308614 2018 10 11 1528-1140 2018 Oct 10 Annals of surgery Ann. Surg. Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer. 10.1097/SLA.0000000000002985 To determine whether prognostic nutritional index (PNI) affects clinical outcome through local immunity in esophageal cancers. PNI is an indicator of nutritional status (...) and systemic immune competence, and has attracted attention as a prognostic biomarker. Tumor-infiltrating lymphocytes (TILs) are a specific histological feature of human cancers, reflecting an individual's immunological tumor response. Using a nonbiased database of 337 curatively resected esophageal cancers, we evaluated the relationship between PNI, TILs status, CD8 expression by immunohistochemical staining, and clinical outcome. Compared with PNI-high cases (n = 220), PNI-low cases (n = 117) showed

EvidenceUpdates2018

44. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis

Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis 30312200 2018 10 12 1528-1140 2018 Oct 11 Annals of surgery Ann. Surg. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis. 10.1097/SLA.0000000000003075 The aim of this study was to perform (...) a systematic review and meta-analysis to assess the accuracy of different surgical axillary staging procedures compared with ALND. Optimal axillary staging after neoadjuvant systemic therapy (NST) in node-positive breast cancer is an area of controversy. Several less invasive procedures, such as sentinel lymph node biopsy (SLNB), marking axillary lymph node with radioactive iodine seed (MARI), and targeted axillary dissection (a combination of SLNB and a MARI-like procedure), have been proposed to replace

EvidenceUpdates2018

45. Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis

Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis 30353058 2018 10 24 1572-0241 2018 Oct 23 The American journal of gastroenterology Am. J. Gastroenterol. Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis. 10.1038/s41395-018-0354-7 Patients with longstanding ulcerative colitis (UC) and colonic Crohn's disease (CD) have (...) an increased risk of colorectal cancer (CRC). We assess the effectiveness of endoscopic surveillance in patients with inflammatory bowel disease (IBD) for diagnosing CRC and reducing CRC-related mortality. MEDLINE, EMBASE, and CENTRAL were searched from inception to 19 September 2016. Randomized controlled trials (RCTs), observational cohorts, or case-control studies assessing any form of endoscopic surveillance for early CRC detection were eligible for inclusion; studies without a comparison non

EvidenceUpdates2018

46. Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial

Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial 30308612 2018 10 11 1528-1140 2018 Oct 10 Annals of surgery Ann. Surg. Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial. 10.1097/SLA.0000000000003031 The standard curative treatment for patients (...) with esophageal cancer is perioperative chemotherapy or preoperative chemoradiotherapy followed by open transthoracic esophagectomy (OTE). Robot-assisted minimally invasive thoracolaparoscopic esophagectomy (RAMIE) may reduce complications. A single-center randomized controlled trial was conducted, assigning 112 patients with resectable intrathoracic esophageal cancer to either RAMIE or OTE. The primary endpoint was the occurrence of overall surgery-related postoperative complications (modified Clavien-Dindo

EvidenceUpdates2018

47. Fosaprepitant (IVEMEND) - prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy

Fosaprepitant (IVEMEND) - prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy Fosaprepitant (IVEMEND ® ). Reference number 3789. Page 1 of 3 AWMSG Secretariat Assessment Report – Limited submission Fosaprepitant (IVEMEND ® ) 150 mg powder for solution for infusion Company: Merck Sharp & Dohme Ltd Licensed indication under consideration: Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy (...) to be of minimal budgetary impact. Clinical effectiveness ? Fosaprepitant has been in use in Wales for adults since 2009. It did not meet the criteria for appraisal by the All Wales Medicines Strategy Group (AWMSG), as its marketing authorisation date for the adult population was granted before 1 October 2010. This submission considers a licence extension for fosaprepitant for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged from 6

All Wales Medicines Strategy Group2018

48. Limited Evidence Suggests Periodontal Disease Is Associated with a Slightly Increased Risk of Breast Cancer

Limited Evidence Suggests Periodontal Disease Is Associated with a Slightly Increased Risk of Breast Cancer UTCAT3364, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Limited Evidence Suggests Periodontal Disease Is Associated with a Slightly Increased Risk of Breast Cancer Clinical Question In female patients with periodontal disease, is there an increased risk for breast cancer when compared to women without (...) periodontal disease? Clinical Bottom Line Patients with periodontitis have a slightly increased risk of breast cancer according to limited evidence from one meta-analysis and a prospective cohort study. History of smoking may play a role in this relationship and more evidence is required before specific recommendations can be made to patients with periodontitis. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1

UTHSCSA Dental School CAT Library2018

49. Treatment algorithm for Cancer-associated Thrombosis (CAT)

Treatment algorithm for Cancer-associated Thrombosis (CAT) TREATMENT ALGORITHM IN CANCER-ASSOCIATED THROMBOSIS, Carrier et al. 329 Current Oncology, Vol. 25, No. 5, October 2018 © 2018 Multimed Inc. PRACTICE GUIDELINE Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus M. Carrier md ms c,* N. Blais md ms c, † M. Crowther md ms c, ‡ P . Kavan md p hd , § G. Le Gal md p hd ,* O. Moodley md , || S. Shivakumar md , # V. Tagalakis md ms c,** C. Wu md , †† and A.Y.Y. Lee md (...) ms c ‡‡ ABSTRACT Management of anticoagulant therapy for the treatment of venous thromboembolism (vte) in cancer patients is complex because of an increased risk of recurrent vte and major bleeding complications in those patients relative to the general population. Subgroups of patients with cancer also show variation in their risk for recurrent vte and adverse bleeding events. Accordingly, a committee of 10 Canadian clinical experts developed the consensus risk- stratification treatment

Thrombosis Interest Group of Canada2018

50. SHTG: Robot-assisted surgery compared with laparoscopic resection for the treatment of rectal cancer

SHTG: Robot-assisted surgery compared with laparoscopic resection for the treatment of rectal cancer SHTG Advice Statement | 1 Advice Statement 013-18 November 2018 Advice Statement Robot-assisted surgery compared with laparoscopic resection for the treatment of rectal cancer Advice for NHSScotland Robot-assisted surgery should be considered for patients with rectal cancer who have a narrow pelvis, are obese (BMI=30), and/or have a tumour located in the mid-to-low rectum. There is evidence (...) of a clinical benefit in the form of reduced risk of conversion to open surgery in these patients, although relevant cost-effectiveness evidence is currently lacking. Expert opinion indicates that conventional laparoscopic options are inadequate for these patients. Data on clinical, oncological and patient-important outcomes should be collected for all robot-assisted surgeries in patients with rectal cancer who meet the criteria outlined above. Provision of robot-assisted surgery for rectal cancer should

SHTG Advice Statements2018

51. SHTG: Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults

SHTG: Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults SHTG Advice Statement | 1 Advice Statement 014-18 November 2018 Advice Statement Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer Advice for NHSScotland Colon capsule endoscopy (CCE-2) is not recommended for routine use in NHSScotland for the detection of colorectal (...) polyps and cancer. The clinical effectiveness evidence is currently limited, no relevant published evidence on the cost effectiveness of the technology was identified, and its place in the patient care pathway has still to be established. CCE-2 may however be considered as an additional testing option in patients who are able to undergo the intensive bowel cleansing needed for CCE-2 and who have contraindications for optical colonoscopy or CT colonography. CCE-2 has the potential to be delivered

SHTG Advice Statements2018

52. Pertuzumab (Perjeta) - treatment of adult patients with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence

Pertuzumab (Perjeta) - treatment of adult patients with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence 1 Published 10 December 2018 1 SMC2119 pertuzumab 420mg concentrate for solution for infusion (Perjeta®) Roche Products Limited Resubmission 9 November 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use (...) in NHSScotland. The advice is summarised as follows: ADVICE: following a second resubmission assessed under the orphan medicine process pertuzumab (Perjeta ® ) is accepted for use within NHSScotland. Indication under review: for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. In a phase II study conducted in women with locally advanced, inflammatory

Scottish Medicines Consortium2018

53. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation

Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search (...) above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Low-dose CT screening may be effective in reducing lung cancer mortality, but there is considerable uncertainty around effectiveness and value. {{author}} {{($index , , , , , , & . Tristan Snowsill 1, * , Huiqin Yang 1 , Ed Griffin 1 , Linda Long 1 , Jo Varley-Campbell 1 , Helen Coelho 1 , Sophie Robinson 1 , Chris Hyde 1, 2 1 Peninsula Technology Assessment

NIHR HTA programme2018

54. Vandetanib for treating medullary thyroid cancer

Vandetanib for treating medullary thyroid cancer V Vandetanib for treating medullary andetanib for treating medullary th thyroid cancer yroid cancer T echnology appraisal guidance Published: 12 December 2018 nice.org.uk/guidance/ta550 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Vandetanib for treating medullary thyroid cancer (TA550) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1 Recommendations 4 2 Information about vandetanib 5 3 Committee discussion 6 The condition and current

National Institute for Health and Clinical Excellence - Technology Appraisals2018

55. Padeliporfin for untreated localised prostate cancer

Padeliporfin for untreated localised prostate cancer P Padeliporfin for untreated localised adeliporfin for untreated localised prostate cancer prostate cancer T echnology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after (...) and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Padeliporfin for untreated localised prostate cancer (TA546) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations 4 2 Information about padeliporfin 6 3 Committee discussion 7

National Institute for Health and Clinical Excellence - Technology Appraisals2018

56. Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer Drug Approval Package: LORBRENA (lorlatinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LORBRENA (lorlatinib) Company: Pfizer, Inc. Application Number: 210868 Approval Date: 11/02/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter

FDA - Drug Approval Package2018

57. Paclitaxel (Apealea) - cancer of the ovary or surrounding structures

Paclitaxel (Apealea) - cancer of the ovary or surrounding structures 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/791927/2018 EMEA/H/C/004154 Apealea (paclitaxel) An overview of Apealea and why it is authorised in the EU (...) What is Apealea and what is it used for? Apealea is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen). Apealea is given along with a platinum-based medicine, carboplatin, to patients whose disease responds to platinum-based cancer medicines and has come back after initial treatment. Apealea contains the active substance paclitaxel. How is Apealea

European Medicines Agency - EPARs2018

58. Pegfilgrastim (Fulphila) - cancer patients to help with neutropenia

Pegfilgrastim (Fulphila) - cancer patients to help with neutropenia 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/653833/2018 EMEA/H/C/004915 Fulphila (pegfilgrastim) An overview of Fulphila and why it is authorised (...) in the EU What is Fulphila and what is it used for? Fulphila is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever). Fulphila is not intended for use in patients with the blood cancer

European Medicines Agency - EPARs2018

59. Pegfilgrastim (Pelmeg) - cancer patients to help with neutropenia

Pegfilgrastim (Pelmeg) - cancer patients to help with neutropenia 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/653835/2018 EMEA/H/C/004700 Pelmeg (pegfilgrastim) An overview of Pelmeg and why it is authorised in the EU What (...) is Pelmeg and what is it used for? Pelmeg is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever). Pelmeg is not intended for use in patients with the blood cancer chronic myeloid leukaemia

European Medicines Agency - EPARs2018

60. Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC)

Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/674777/2018 EMEA/H/C/004248 Alunbrig (brigatinib) An overview of Alunbrig and why it is authorised in the EU What (...) is Alunbrig and what is it used for? Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) who have been treated before with a cancer medicine called crizotinib. Alunbrig is used on its own and only if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain changes affecting the gene that makes a protein called ALK (anaplastic lymphoma kinase). Alunbrig contains the active substance brigatinib. How is Alunbrig

European Medicines Agency - EPARs2018